Liposomes in the treatment of inflammatory disorders

Bibliography

• ALLEN TM, CULLIS PR: Drug delivery systems: entering the mainstream. Science (2004) 303:1818–1822
   PubMed Web of Science ®Google Scholar
• ••A recent comprehensive review on drugcarrier systems in general
   Google Scholar
• STORM G, CROMMELIN DJ: Liposomes: quo vadis? Pharm. Sci. Technol Today (1998) 1:19–25
   Google Scholar
• METSELAAR JM, MASTROBATTISTA E, STORM G: Liposomes for intravenous drug targeting: design and applications. Mini Rev. Med. Chem. (2002) 2:319–329
   PubMed Web of Science ®Google Scholar
• SHAW IH, KNIGHT CG, THOMAS DP, PHILLIPS NC, DINGLE JT: Liposome-incorporated corticosteroids: I. The interaction of liposomal cortisol palmitate with inflammatory synovial membrane. Br. J. Exp. Pathol (1979) 60:142–150
   PubMed Web of Science ®Google Scholar
• PHILLIPS NC, THOMAS DP, KNIGHT CG, DINGLE JT: Liposome-incorporated corticosteroids. II. Therapeutic activity in experimental arthritis. Ann. Rheum. Dis. (1979) 38:553–557
   PubMed Web of Science ®Google Scholar
• DE SILVA M, HAZLEMAN BL, THOMAS DP, WRAIGHT P: Liposomes in arthritis: a new approach. Lancet (1979) 1:1320–1322
   PubMed Web of Science ®Google Scholar
• BONANOMI MH, VELVART M, STIMPEL M, ROOS KM, FEHR K, WEDER HG: Studies of pharmacokinetics and therapeutic effects of glucocorticoids entrapped in liposomes after intraarticular application in healthy rabbits and in rabbits with antigen-induced arthritis. Rheumatol Int. (1987) 7:203–212
   PubMed Web of Science ®Google Scholar
• LOPEZ-GARCIA F, VAZQUEZ-AUTON JM, GIL F et al.: Intra-articular therapy of experimental arthritis with a derivative of triamcinolone acetonide incorporated in liposomes. Pharm. Pharmacol (1993) 45:576–578
   PubMed Web of Science ®Google Scholar
• KORTING HC, ZIENICKE H, SCHAFER-KORTING M, BRAUN-FALCO 0: Liposome encapsulation improves efficacy of betamethasone dipropionate in atopic eczema but not in psoriasis vulgaris. Eur. Clin. Pharmacol (1990) 39:349–351
   Web of Science ®Google Scholar
• TREMBLAY GM, THERIEN HM, ROCHELEAU H, CORMIER Y: Liposomal dexamethasone effectiveness in the treatment of hypersensitivity pneumonitis in mice. Eur. J. Clin. Invest. (1993) 23:656–661
   PubMed Web of Science ®Google Scholar
• DIMATTEO M, REASOR MJ: Modulation of silica-induced pulmonary toxicity by dexamethasone-containing liposomes. Toxicol Appl. Pharmacol (1997) 142:411–421
   PubMed Web of Science ®Google Scholar
• SUNTRES ZE, SHEK PN: Liposomes promote pulmonary glucocorticoid delivery. J. Drug Target. (1998) 6:175–182
   PubMed Web of Science ®Google Scholar
• SUNTRES ZE, SHEK PN: Prophylaxis against lipopolysaccharide-induced lung injuries by liposome-entrapped dexamethasone in rats. Biochem. Pharmacol (2000) 59:1155–1161
   PubMed Web of Science ®Google Scholar
• WALDREP JC, GILBERT BE, KNIGHT CM et al.: Pulmonary delivery of beclomethasone liposome aerosol in volunteers. Tolerance and safety. Chest (1997) 111:316–323
   PubMed Web of Science ®Google Scholar
• SAARI SM, VIDGREN MT, KOSKINEN MO, TURJANMAA VM, WALDREP JC, NIEMINEN MM: Regional lung deposition and clearance of 99mTc-labeled beclomethasone-DLPC liposomes in mild and severe asthma. Chest (1998) 113:1573–1579
   PubMed Web of Science ®Google Scholar
• JOSHI M, MISRA AN: Pulmonary disposition of budesonide from liposomal dry powder inhaler. Methods Find. Exp. Clin. Pharmacol (2001) 23:531–536
   PubMed Web of Science ®Google Scholar
• KONDURI KS, NANDEDKAR S, DUZGUNES N et al.: Efficacy of liposomal budesonide in experimental asthma. Allergy Clin. Immunol (2003) 111:321–327
   Google Scholar
• GILBERT BE, KNIGHT C, ALVAREZ FG et al.: Tolerance of volunteers to cyclosporine A-dilauroylphosphatidylcholine liposome aerosol. Am. J. Respir. Crit. Care Med. (1997) 156:1789–1793
   PubMed Web of Science ®Google Scholar
• LETSOU GV, SAFI HJ, REARDON MJ et al.: Pharmacokinetics of liposomal aerosolized cyclosporine A for pulmonary immunosuppression. Ann. Thorac. Surg. (1999) 68: 2044–2048
   Google Scholar
• TING WW, SONTHEIMER RD: Local therapy for cutaneous and systemic lupus erythematosus: practical and theoretical considerations. Lupus (2001) 10:171–184
   PubMed Web of Science ®Google Scholar
• CEVC G: Transfersomes, liposomes and other lipid suspensions on the skin: permeation enhancement, vesicle penetration, and transdermal drug delivery. Crit. Rev. Ther. Drug Carrier Syst. (1996) 13:257–388
   PubMed Web of Science ®Google Scholar
• •An overview of carrier systems and drug delivery techniques that aim at passage over the skin barrier
   Google Scholar
• CEVC G, BLUME G: Biological activity and characteristics of triamcinolone-acetonide formulated with the self-regulating drug carriers, transfersomes. Biochim. Biophys. Acta (2003) 1614:156–164
   PubMed Web of Science ®Google Scholar
• CEVC G, BLUME G: Hydrocortisone and dexamethasone in very deformable drug carriers have increased biological potency, prolonged effect, and reduced therapeutic dosage. Biochim. Biophys. Acta (2004) 1663:61–73
   PubMed Web of Science ®Google Scholar
• CEVC G, BLUME G: New, highly efficient formulation of diclofenac for the topical, transdermal administration in ultradeformable drug carriers, Transfersomes. Biochim. Biophys. Acta (2001) 1514:191–205
   PubMed Web of Science ®Google Scholar
• TROTTA M, PEIRA E, DEBERNARDI F, GALLARATE M: Elastic liposomes for skin delivery of dipotassium glycyrrhizinate. Int. Pharm. (2002) 241:319–327
   PubMed Web of Science ®Google Scholar
• TROTTA M, PEIRA E, CARLOTTI ME, GALLARATE M: Deformable liposomes for dermal administration of methotrexate. Int. J. Pharm. (2004) 270:119–125
   PubMed Web of Science ®Google Scholar
• ERDOGAN M, WRIGHT JR Jr, MCALISTER VC: Liposomal tacrolimus lotion as a novel topical agent for treatment of immune-mediated skin disorders: experimental studies in a murine model. Br. Dermatol (2002) 146:964–967
   PubMed Web of Science ®Google Scholar
• VERMA DD, FAHR A: Synergistic penetration enhancement effect of ethanol and phospholipids on the topical delivery of cyclosporin A. J. Control. Release (2004) 97:55–66
   PubMed Web of Science ®Google Scholar
• VERMA DD, VERMA S, MCELWEE KJ, FREYSCHMIDT-PAUL P, HOFFMAN R, FAHR A: Treatment of alopecia areata in the DEBR model using cyclosporin A lipid vesicles. Eur. J. Dermatol (2004) 14:332–338
   PubMed Web of Science ®Google Scholar
• VAN ROOIJEN N, VAN NIEUWMEGEN R: Elimination of phagocytic cells in the spleen after intravenous injection of liposome encapsulated dichloromethylene-diphosphonate. An enzyme-histochemical study. Cell Tissue Res. (1984) 238:355–358
   PubMed Web of Science ®Google Scholar
• VAN LENT PL, AN DEN BERSSELAAR L, VAN DEN HOEK AE et al.: Reversible depletion of synovial lining cells after intra-articular treatment with liposome- encapsulated dichloromethylene diphosphonate. Rheumatol. Int. (1993) 13:21–30
   PubMed Web of Science ®Google Scholar
• VAN LENT PL, HOLTHUYSEN AE, VAN ROOIJEN N, VAN DE PUTTE LB, VAN DEN BERG WB. Local removal of phagocytic synovial lining cells by clodronate-liposomes decreases cartilage destruction during collagen type II arthritis. Ann. Rheum. Dis. (1998) 57:408–413
   PubMed Web of Science ®Google Scholar
• BARRERA P, BLOM A, VAN LENT PL et al.: Synovial macrophage depletion with clodronate-containing liposomes in rheumatoid arthritis. Arthritis Rheum. (2000) 43:1951–1959
   PubMed Web of Science ®Google Scholar
• •The first paper proving the concept of macrophage depletion with liposomal clodronate in the clinical setting
   Google Scholar
• VAN ROOIJEN N, VAN KESTEREN-HENDRIKX E: Cloclronate liposomes: perspectives in research and therapeutics.Lip osome Res. (2002) 12:81–94
   PubMed Web of Science ®Google Scholar
• VORAUER-UHL K, FURNSCHLIEF E, WAGNER A, FERKO B, KATINGER H: Topically applied liposome encapsulated superoxide dismutase reduces postburn wound size and edema formation. Eur. J. Pharm. Sci. (2001) 14:63–67
   PubMed Web of Science ®Google Scholar
• PETELIN M, PAVLICA Z, IVANUSA T,SENTJURC M, SKALERIC U: Local delivery of liposome-encapsulated superoxide dismutase and catalase suppress periodontal inflammation in beagles. J. Clin. Periodontol (2000) 27:918–925
   PubMed Web of Science ®Google Scholar
• GALOVIC RENGEL R, BARISIC K, PAVELIC Z, ZANIC GRUBISIC T, CEPELAK I, FILIPOVIC-GRCIC J: High efficiency entrapment of superoxide dismutase into mucoadhesive chitosan-coated liposomes. Eur. J. Pharm. Sci. (2002) 15:441–448
   PubMed Web of Science ®Google Scholar
• TRIF M, GUILLEN C, VAUGHAN DM et al.: Liposomes as possible carriers for lactoferrin in the local treatment of inflammatory diseases. Exp. Biol. Med. (2001) 226:559–564
   PubMed Web of Science ®Google Scholar
• MEYER KB, THOMPSON MM, LEVY MY, BARRON LG, SZOKA FC Jr: Intratracheal gene delivery to the mouse airway: characterization of plasmid DNA expression and pharmacokinetics. Gene Ther. (1995) 2:450–460
   PubMed Web of Science ®Google Scholar
• YE J, WANG L, ZHANG X, TANTISHAIYAKUL V, ROJANASAKULY: Inhibition of TNF-alpha gene expression and bioactivity by site-specific transcription factor-binding oligonucleotides. Am. J. PhysioL Lung Cell Mol PhysioL (2003) 284:L386–L394
   PubMed Web of Science ®Google Scholar
• STENTON GR, ULANOVA M, DERY RE et al.: Inhibition of allergic inflammation in the airways using aerosolized antisense to Syk kinase. Immunol (2002) 169:1028–1036
   Web of Science ®Google Scholar
• ULANOVA M, PUTTAGUNTA L, KIM MK, SCHREIBER AD, BEFUS AD: Antisense oligonucleotides to Syk kinase: a novel therapeutic approach for respiratory disorders. Curr. Opin. Investig. Drugs (2003) 4:552–555
   PubMedGoogle Scholar
• TOMITA T, TAKEUCHI E, TOMITA N et al.: Suppressed severity of collagen-induced arthritis by in vivo transfection of nuclear factor kappaB decoy oligodeoxynucleotides as a gene therapy. Arthritis Rheum. (1999) 42:2532–2542
   PubMed Web of Science ®Google Scholar
• TOMITA T, TAKANO H, TOMITA N et al.: Transcription factor decoy for NFlcappaB inhibits cytokine and adhesion molecule expressions in synovial cells derived from rheumatoid arthritis. Rheumatology (2000) 39:749–757
   PubMed Web of Science ®Google Scholar
• FATTAL E, COUVREUR P, DUBERNET C: 'Smart' delivery of antisense oligonucleotides by anionic pH-sensitive liposomes. Adv. Drug Deli v. Rev. (2004) 56:931–946
   PubMed Web of Science ®Google Scholar
• •Nice introduction to the different techniques that are currently investigated for intracellular nucleotide delivery
   Google Scholar
• AGARWAL R, KATARE OP, VYAS SP: Preparation and in vitro evaluation of liposomal/niosomal delivery systems for antipsoriatic drug dithranol. Int. J. Pharm. (2001) 228:43–52
   PubMed Web of Science ®Google Scholar
• AGARWAL R, SARASWAT A. KAUR I, KATARE OP, KUMAR B: A novel liposomal formulation of dithranol for psoriasis: preliminary results. J. Dermatol (2002) 29:529–532
   PubMed Web of Science ®Google Scholar
• PATEL VB, MISRA AN, MARFATIA YS: Preparation and comparative clinical evaluation of liposomal gel of benzoyl peroxide for acne. Drug Dev. Ind. Pharm. (2001) 27:863–869
   PubMed Web of Science ®Google Scholar
• PATEL VB, MISRA A, MARFATIA YS: Topical liposomal gel of tretinoin for the treatment of acne: research and clinical implications. Pharm. Dev. TechnoL (2000) 5:455–464
   PubMed Web of Science ®Google Scholar
• MAEDA H, WU J, SAWA T, MATSUMURA Y, HORT K: Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review.J. Control. Release (2000) 65:271–284
   PubMed Web of Science ®Google Scholar
• MAEDA H, SAWA T, KONNO T: Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J. Control. Release (2001) 74:47–61
   PubMed Web of Science ®Google Scholar
• MIZUSHIMA Y, HAMANO T, YOKOYAMA K: Tissue distribution and anti-inflammatory activity of corticosteroids incorporated in lipid emulsion. Ann. Rheum. Dis. (1982) 41:263–267
   PubMed Web of Science ®Google Scholar
• MIZUSHIMA Y, WADA Y, ETOH Y, WATANABE K: Anti-inflammatory effects of indomethacin ester incorporated in a lipid microsphere. j Pharm. Pharmacol. (1983) 35:398–399
   PubMed Web of Science ®Google Scholar
• MIZUSHIMA Y: Lipid microspheres as novel drug carriers. Drugs Exp. Clin. Res. (1985) 11:595–600
   PubMedGoogle Scholar
• SHOJI Y, MIZUSHIMA Y, YANAGAWA A, YONAHA T: Electron microscopic studies on tissue distribution of lipid microspheres used as drug delivery carriers. Drugs Exp. Clin. Res. (1985) 11:601–609
   PubMedGoogle Scholar
• OTOMO S, MIZUSHIMA Y, AIHARA H, YOKOYAMA K, WATANABE M, YANAGAWA A: Prostaglandin El incorporated in lipid microspheres (lipo PGE1). Drugs Exp. Clin. Res. (1985) 11:627–631
   PubMedGoogle Scholar
• SMEESTERS C, GIROUX L, VINET B et al.: Efficacy of incorporating cyclosporine into liposomes to reduce its nephrotoxicity. Can. J. Surg-. (1988) 31:34–36
   PubMed Web of Science ®Google Scholar
• GORECKI DC, JAKOBISIAK M, KRUSZEWSKI A. LASEK W: Evidence that liposome incorporation of cyclosporine reduces its toxicity and potentiates its ability to prolong survival of cardiac allografts in mice. Transplantation (1991) 52:766–769
   PubMed Web of Science ®Google Scholar
• FREISE CE, LIU T, HONG K, OSORIO RW et al.: The increased efficacy and decreased nephrotoxicity of a cyclosporine liposome. Transplantation (1994) 57:928–932
   PubMed Web of Science ®Google Scholar
• KO S, NAKAJIMA Y, KANEHIRO H et al.: The enhanced immunosuppressive efficacy of newly developed liposomal FK506 in canine liver transplantation. Transplantation (1995) 59:1384–1388
   PubMed Web of Science ®Google Scholar
• KO S, NAKAJIMA Y, KANEHIRO H, HORIKAWA M et al.: Different immunosuppressive effects of liposomal FK506 in liver and kidney transplantation. Transplant. Proc. (1996) 28:1066–1068
   PubMed Web of Science ®Google Scholar
• KO S, NAKAJIMA Y, KANEHIRO H et al.: Predominant role of local immunosuppressive effect in enhanced efficacy of liposomal FK506 in organ transplantation. Transplant. Proc. (1997) 29:529–531
   PubMed Web of Science ®Google Scholar
• LOVE WG, AMOS N, KELLAWAY IW, WILLIAMS BD: Specific accumulation of cholesterol-rich liposomes in the inflammatory tissue of rats with adjuvant arthritis. Ann. Rheum. Dis. (1990) 49:611–614
   PubMed Web of Science ®Google Scholar
• LOVE WG, AMOS N, KELLAWAY IW, WILLIAMS BD: Specific accumulation of technetium-99m radiolabelled, negative liposomes in the inflamed paws of rats with adjuvant induced arthritis: effect of liposome size. Ann. Rheum. Dis. (1989) 48:143–148
   PubMed Web of Science ®Google Scholar
• ALLEN TM, HANSEN C, RUTLEDGE J: Liposomes with prolonged circulation times: factors affecting uptake by reticuloendothelial and other tissues. Biochim. Biophys. Acta (1989) 981:27–35
   PubMed Web of Science ®Google Scholar
• ALLEN TM, HANSEN C, MARTIN F, REDEMANN C, YAU-YOUNG A: Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim. Biophys. Acta (1991) 1066:29–36
   PubMed Web of Science ®Google Scholar
• LASIC DD, PAPAHADJOPOULOS D: Liposomes revisited. Science (1995) 267:1275–1276
   PubMed Web of Science ®Google Scholar
• •Illustration of the development of modern liposomal drug delivery techniques, in particular passive targeting with long-circulating liposomes
   Google Scholar
• OYEN WJ, BOERMAN OC, STORM G et al: Detecting infection and inflammation with technetium-99m-labeled Stealth liposomes. J. Nud Med. (1996) 37:1392–1397
   Web of Science ®Google Scholar
• BOERMAN OC, OYEN WJ, STORM G et al: Technetium-99m labelled liposomes to image experimental arthritis. Ann. Rheum. Dis. (1997) 56:369–373
   PubMed Web of Science ®Google Scholar
• OYEN WJ, BOERMAN OC, DAMS ET et al: Scintigraphic evaluation of experimental colitis in rabbits. J. Nud Med. (1997) 38:1596–1600
   Web of Science ®Google Scholar
• AWASTHI V, GOINS B, KLIPPER R, LOREDO R, KORVICK D, PHILLIPS WT: Imaging experimental osteomyelitis using radiolabeled liposomes. Nud Med. (1998) 39:1089–1094
   Google Scholar
• LAVERMAN P, BOERMAN OC, OYEN WJ, DAMS ET, STORM G, CORSTENS FH: Liposomes for scintigraphic detection of infection and inflammation. Adv. DrugDeliv. Rev. (1999) 37:225–235
   PubMed Web of Science ®Google Scholar
• BOERMAN OC, LAVERMAN P, OYEN WJ, CORSTENS FH, STORM G: Radiolabeled liposomes for scintigraphic imaging. Prog. Lipid Res. (2000) 39:461–475
   PubMed Web of Science ®Google Scholar
• BOERMAN OC, DAMS ET, OYEN WJ, CORSTENS FH, STORM G: Radiopharmaceuticals for scintigraphic imaging of infection and inflammation. Inflamm. Res. (2001) 50:55–64
   PubMed Web of Science ®Google Scholar
• AWASTHI VD, GOINS B, KLIPPER R, PHILLIPS WT: Accumulation of PEG-liposomes in the inflamed colon of rats: potential for therapeutic and diagnostic targeting of inflammatory bowel diseases. J. Drug Target. (2002) 10:419–427
   PubMed Web of Science ®Google Scholar
• DAMS ET, OYEN WJ, BOERMAN OC et al.: 99mTc-PEG liposomes for the scintigraphic detection of infection and inflammation: clinical evaluation. J. Nucl. Med. (2000) 41:622–630
   PubMed Web of Science ®Google Scholar
• •The first paper proving the concept of passive targeting with long-circulating liposomes to sites of inflammation in the
   Google Scholar
• BROUWERS AH, DE JONG DJ, DAMS ET et al: Tc-99m-PEG-liposomes for the evaluation of colitis in Crohn's disease. J. Drug Target. (2000) 8:225–233
   PubMed Web of Science ®Google Scholar
• WILLIAMS AS, CAMILLERI JP, WILLIAMS BD: Suppression of adjuvant-induced arthritis by liposomally conjugated methotrexate in the rat. Br. J. Rheumatol (1994) 33:530–533
   PubMedGoogle Scholar
• WILLIAMS AS, CAMILLERI JP, AMOS N, WILLIAMS BD: Differential effects of methotrexate and liposomally conjugated methotrexate in rat adjuvant-induced arthritis. Clin. Exp. Immunol (1995) 102:560–565
   PubMed Web of Science ®Google Scholar
• WILLIAMS AS, JONES SG, GOODFELLOW RM, AMOS N, WILLIAMS BD: Interleukin-lbeta (IL-lbeta) inhibition: a possible mechanism for the anti-inflammatory potency of liposomally conjugated methotrexate formulations in arthritis. Br. J. Pharmacol (1999) 128: 234–240
   Google Scholar
• WILLIAMS A, GOODFELLOW R, TOPLEY N, AMOS N, WILLIAMS B: The suppression of rat collagen-induced arthritis and inhibition of macrophage derived mediator release by liposomal methotrexate formulations. Inflamm. Res. (2000) 49:155–161
   PubMed Web of Science ®Google Scholar
• CORVO ML, BOERMAN OC, OYEN WJ et al.: Intravenous administration of superoxide dismutase entrapped in long circulating liposomes. II. In vivo fate in a rat model of adjuvant arthritis. Biochim. Biophys. Acta (1999) 1419:325–334
   PubMed Web of Science ®Google Scholar
• LUISA CORVO M, JORGE JC, VAN'T HOF R, CRUZ ME, CROMMELIN DJ, STORM G: Superoxide dismutase entrapped in long-circulating liposomes: formulation design and therapeutic activity in rat adjuvant arthritis. Biochim. Biophys. Acta (2002) 1564:227–236
   PubMed Web of Science ®Google Scholar
• METSELAAR JM, WAUBEN MH, WAGENAAR-HILBERS JP, BOERMAN OC, STORM G: Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes. Arthritis Rheum. (2003) 48:2059–2066
   PubMed Web of Science ®Google Scholar
• •The most impressive predinical results achieved so far with passive liposomal targeting to sites of inflammation
   Google Scholar
• METSELAAR JM, VAN DEN BERG WB, HOLTHUYSEN AE, WAUBEN MH, STORM G, VAN LENT PL: Liposomal targeting of glucocorticoids to synovial lining cells strongly increases therapeutic benefit in collagen type II arthritis. Ann. Rheum. Dis. (2004) 63:348–353
   PubMed Web of Science ®Google Scholar
• SCHMIDT J, METSELAAR JM, WAUBEN MH, TOYKA KV, STORM G, GOLD R: Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis. Brain (2003) 126:1895–1904
   PubMed Web of Science ®Google Scholar
• SCHMIDT J, METSELAAR JM, GOLD R: Intravenous liposomal prednisolone downregulates in situ TNF-alpha production by T-cells in experimental autoimmune encephalomyelitis. Histochem. Cytochem. (2003) 51:1241–1244
   PubMed Web of Science ®Google Scholar
• RICHARDS PJ, WILLIAMS AS, GOODFELLOW RM, WILLIAMS BD: Liposomal clodronate eliminates synovial macrophages, reduces inflammation and ameliorates joint destruction in antigen-induced arthritis. Rheumatology (1999) 38:818–825
   PubMed Web of Science ®Google Scholar
• RICHARDS PJ, WILLIAMS BD, WILLIAMS AS: Suppression of chronic streptococcal cell wall-induced arthritis in Lewis rats by liposomal clodronate. Rheumatology (2001) 40:978–987
   PubMed Web of Science ®Google Scholar
• KONING GA, SCHIFFELERS RM, STORM G: Endothelial cells at inflammatory sites as target for therapeutic intervention. Endothelium (2002) 9:161–171
   PubMed Web of Science ®Google Scholar
• CROMMELIN DJ, VAN RENSEN AJ, WAUBEN MH, STORM G: Liposomes in autoimmune diseases: selected applications in immunotherapy and inflammation detection./ Control. Release (1999) 62:245–251
   PubMed Web of Science ®Google Scholar
• THURSTON G, MCLEAN JW, RIZEN M et al.: Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J. Clin. Invest. (1998) 101:1401–1413
   PubMed Web of Science ®Google Scholar
• KESSNER S, KRAUSE A, ROTHE U, BENDAS G: Investigation of the cellular uptake of E-selectin-targeted immunoliposomes by activated human endothelial cells. Biochim. Biophys. Acta (2001) 1514:177–190
   PubMed Web of Science ®Google Scholar
• MASTROBATTISTA E, STORM G, VAN BLOOIS L et al.: Cellular uptake of liposomes targeted to intercellular adhesion molecule-1 (ICAM-1) on bronchial epithelial cells. Biochim. Biophys. Acta (1999) 1419:353–363
   PubMed Web of Science ®Google Scholar
• SCHIFFELERS RM, MOLEMA G, TEN HAGEN TL et al.: Ligand-targeted liposomes directed against pathological vasculature. J. Lip osome Res. (2002) 12:129–135
   PubMed Web of Science ®Google Scholar
• EVERTS M, KONING GA, KOK RJ et al.: In vitro cellular handling and in vivo targeting of E-selectin-directed immunoconjugates and immunoliposomes used for drug delivery to inflamed endothelium. Pharm. Res. (2003) 20:64–72
   PubMed Web of Science ®Google Scholar
• •One of the few papers reporting in vivo work on active targeting with liposome systems to sites of inflammation
   Google Scholar
• VAN RENSEN AJ, TAAMS LS, GROSFELD-STULEMEYER MC, VAN EDEN W, CROMMELIN DJ, WAUBEN MH: Induction of T cell anergy by liposomes with incorporated major histocompatibility complex (MHC) II/ peptide complexes. Pharm. Res. (2000) 17:720–726
   PubMed Web of Science ®Google Scholar
• BOOT EP, KONING GA, STORM G et al.: CD134 as targetfor specific drug delivery to auto-aggressive CD4* T cells in adjuvantarthritis. Arthrit. Res. Therapy (2005) 7:R604–R615
   PubMed Web of Science ®Google Scholar
• FESQ H, LEHMANN J, KONTNY A et al.: Improved risk-benefit ratio for topical triamcinolone acetonide in transfersome in comparison with equipotent cream and ointment: a randomized controlled trial. Br. Dermatol (2003) 149:611–619
   PubMed Web of Science ®Google Scholar
• YOSHIKAWA H, YAMAZAKI S, ABET, ODA Y: Liposteroid therapy for refractory seizures in children. J. Child Neurol (2000) 15:702–704
   PubMed Web of Science ®Google Scholar
• HOSHI K, MIZUSHIMAY, SHIOKAWAY, et al.: Double-blind study with liposteroid in rheumatoid arthritis. Drugs Exp. Clin. Res. (1985) 11:621–626
   PubMedGoogle Scholar